Chemical Structure (Oxcarbazepine 01)
Oxcarbazepine Tablet, Film Coated
Product Images NDC 51991-293
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 51991-293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Oxcarbazepine 02)
Figure 2 (Oxcarbazepine 03)
The given text provides the seizure rate and the p-value obtained from a log-rank test. The graph shows the number of days from the 1st dose to the 1st seizure for two treatment groups: Oxcarbazepine and Placebo. Therefore, it can be inferred that the provided information is related to a study on the effectiveness of Oxcarbazepine in preventing seizures.*
Figure 3 (Oxcarbazepine 04)
Figure 4 (Oxcarbazepine 05)
The text appears to be a plot or a figure showing the time to exit in days for two treatment groups - HIGH and LOW. There is also information about the p-value of the log-rank test. It is not possible to provide a more specific description without further context.*
Principal Display Panel (150 mg Bottle Label)
This is a medication that comes in the form of a film-coated tablet containing 150mg of oxcarbazepine per tablet. The dosage and full product information can be found in the insert. The tablets contain FD&C Yellow No.5 as a color additive and must be kept in a tight container, away from children. Recommended storage temperature is between 20-25°C with permitted excursions to 15-30°C. The medication should be dispensed with a medication guide to each patient. The manufacturer is LGM Pharma Solutions LLC and the distributor is Breckenridge Pharmaceutical Inc. NDC number is 51991-292-01.*
Principal Display Panel (300 mg Bottle Label)
Each film-coated tablet of oxcarbazepine contains 300mg and is distributed by Breckenridge Pharmaceutical, Inc. The tablets may contain FD&C Yellow No. 5 (tartrazine) and should be stored in a tight container between 59-86°F. More information about dosage and usage can be found in the insert provided. This medication should be kept out of reach of children. Manufactured by LGM Pharma Solutions, LLC.*
Principal Display Panel (600 mg Bottle Label)
Each tablet contains 600mg of oxcarbazepine. The dosage and complete product information can be found in the insert. It contains a color additive FDAC Yellow No. 5 (artrazine). The tablet should be stored at 20°-25°C (77°F) with excursions permitted to 15°C-30°C (56°F-86°F). Dispense in tight container (USP). Distributed by Breckenridge Pharmaceutical, Inc. Berlin, CT 06037. It should be kept out of reach of children.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
